Pleurodesis: a comparison of two sclerosing agents for pleural effusions in Mozambique

被引:0
|
作者
Figueiredo, Ivo [1 ]
Cossa, Anilsa [1 ]
Hassane, Anila [1 ]
Sousa, Jose [1 ]
Pondo, Joaquim [1 ]
Teixeira, Joao [2 ]
Akrami, Kevan [3 ]
Graves, Susannah K. [3 ]
Malhotra, Atul [4 ]
Nunes, Elizabete A. [1 ]
机构
[1] Maputo Cent Hosp, Dept Pulmonol, Maputo, Mozambique
[2] Maputo Cent Hosp, Dept Pharmaceut, Maputo, Mozambique
[3] Univ Calif San Diego, Div Infect Dis, 9500 Gilman Dr 0711, San Diego, CA 92093 USA
[4] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA
关键词
Pleurodesis; sodium hydroxide (NaOH); Mozambique; pleural effusion; lung; MANAGEMENT;
D O I
10.21037/jtd.2017.07.102
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Pleural effusions constitute one of the most frequent pathologies encountered in the pulmonary service of Maputo Central Hospital (MCH) in Mozambique. Bleomycin and talc are commonly used for pleurodesis, but cost prohibitive, therefore we aimed to retrospectively compare the efficacy and safety of sodium hydroxide (NaOH) with bleomycin for pleurodesis. Methods: Case records of pleurodesis using bleomycin and NaOH from 2002 to 2013 were reviewed. Standard of care for pleurodesis for recurrent pleural effusions at MCH was developed using the materials available. NaOH remained the agent of choice until 2006 when bleomycin became available. Clinical data regarding general complications, rate of success and lung expansion were noted for every patient who underwent pleurodesis at MCH during this time frame. Results: Review of pleurodesis at MCH revealed 24 cases using bleomycin and 23 cases using NaOH as the sclerosing agent. Patient characteristics were balanced between the two groups with majority of pleural effusions malignant in etiology. Conclusions: There was no statistically significant difference between the use of bleomycin and NaOH as defined by lung expansion. General complications were observed less frequently in 2 (10%) of patients treated with NaOH compared with 8 (38%) of patients using bleomycin. Only three patients presented with recurrent pleural effusion after pleurodesis with NaOH. NaOH may offer a low cost alternative sclerosing agent for resource limited areas.
引用
收藏
页码:3132 / 3137
页数:6
相关论文
共 50 条
  • [21] Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis
    Tremblay, A.
    Mason, C.
    Michaud, G.
    EUROPEAN RESPIRATORY JOURNAL, 2007, 30 (04) : 759 - 762
  • [22] Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions
    Neto, Jose D. A.
    de Oliveira, Sandro F. Q.
    Vianna, Sylvana P.
    Terra, Ricardo M.
    RESPIROLOGY, 2010, 15 (01) : 115 - 118
  • [23] COMPARISON OF SILVER-NITRATE AND TETRACYCLINE AS PLEURAL SCLEROSING AGENTS IN RABBITS
    VARGAS, FS
    TEIXEIRA, LR
    SILVA, LMMF
    CARMO, AO
    LIGHT, RW
    CHEST, 1995, 108 (04) : 1080 - 1083
  • [24] Comparison of nitrogen mustard, cytarabine and dacarbazine as pleural sclerosing agents in rabbits
    Marchi, E
    Vargas, FS
    Teixeira, LR
    Fagundes, DJ
    Silva, LMMF
    Carmo, AO
    Light, RW
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (03) : 598 - 602
  • [25] Predictors of talc pleurodesis outcome in patients with malignant pleural effusions
    Yildirim, Huseyin
    Metintas, Muzaffer
    Ak, Guentuelue
    Metintas, Selma
    Erginel, Sinan
    LUNG CANCER, 2008, 62 (01) : 139 - 144
  • [26] Pleurodesis for recurrent malignant pleural effusions: the quest for the Holy Grail
    Astoul, Philippe
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2011, 40 (02) : 277 - 279
  • [27] Pleurodesis for malignant pleural effusions: current controversies and variations in practices
    West, SD
    Davies, RJO
    Lee, YCG
    CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (04) : 305 - 310
  • [28] Survival Difference in Patients with Malignant Pleural Effusions Treated with Pleural Catheter or Talc Pleurodesis
    Liou, Douglas Z.
    Serna-Gallegos, Derek
    Chan, Joshua L.
    Borgella, Jerald
    Akhmerov, Shah
    Soukiasian, Harmik J.
    AMERICAN SURGEON, 2016, 82 (10) : 995 - 999
  • [29] Systemic Inflammatory Response to Different Sclerosing Agents as a Predictor of Pleurodesis Outcome
    Zablockis, Rolandas
    Danila, Edvardas
    Gruslys, Vygantas
    Cincileviciute, Giedre
    IN VIVO, 2021, 35 (04): : 2391 - 2398
  • [30] Iodopovidone pleurodesis for malignant pleural effusions: an updated systematic review and meta-analysis
    Muthu, Valliappan
    Dhooria, Sahajal
    Sehgal, Inderpaul Singh
    Prasad, Kuruswamy Thurai
    Aggarwal, Ashutosh N.
    Agarwal, Ritesh
    SUPPORTIVE CARE IN CANCER, 2021, 29 (08) : 4733 - 4742